register

News & Trends - Pharmaceuticals

Merck Healthcare and Gedeon Richter step up fertility support amid Ferring treatment shortage

Health Industry Hub | November 2, 2022 |

Pharma News: Ferring Pharmaceuticals has notified the TGA of the current shortage of Menopur 1200 IU and 600 IU injections due to manufacturing issues.

Ferring distributed communications to healthcare professionals locally informing them of the shortage and the suspension of all Menopur shipments “due to changes made in the manufacturing process of Menopur drug substance by third-party supplier”. Ferring Australia said the company “is not aware of any evidence indicating that changes in the manufacturing process pose any risks to patients.”

The regulator told Health Industry Hub “There are multiple other gonadotropins supplied by two other sponsors, available on the Australian market for clinicians to consider during the shortage of Menopur products. The TGA is assessing the supply of the alternative products and if required will take appropriate regulatory action(s) to minimise the impact of the shortage on Australian patients.”

While the local Ferring affiliate has advised the TGA that supply shortages will last until 4 November 2022, globally the company is unable to make a statement on when the product would return to the market.

A Merck Healthcare spokesperson told Health Industry Hub “As a leader in Fertility treatment, Merck understands the importance of a steady and reliable supply of medicine for patients. We are not anticipating any disruption to supply of our portfolio of fertility medicines that includes Pergoveris, Gonal-f, Luveris, Ovidrel and Crinone. Given the recent out of stock reports by other Fertility companies, we will be looking to make stock allocations for medications where we now see an increased use.”

A Gedeon Richter spokesperson advised Health Industry Hub “Gedeon Richter is aware of the current global shortage of Menopur and understand the impact this will be having for both health care professionals and patients currently undergoing ART (Assisted Reproductive Treatment). We are in communication with our customers to offer any support or assistance to ensure patient treatments are not impacted by this issue. Clinics can be reassured that Bemfola’s current and future stock availability in Australia and New Zealand is able to meet any excess demand.”

Merck Healthcare added “We recently notified the TGA and our customers of supply issues with Cetrotide, we anticipate these shortages may last until mid-January 2023. With patient needs front and foremost, we have reserved some stock in case needed for urgent compassionate access requests, and are confident we will be back to full supply levels early next year.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.